INFLAMMATION AND INFLAMMATORY BOWEL DISEASE

Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine

B Thjodleifsson, K Davídsdóttir, U Agnarsson, G Sigthórsson, M Kjeld, I Bjarnason

Background: The safety of infant vaccination has been questioned in recent years. In particular it has been suggested that the measles, mumps, and rubella (MMR) vaccine leads to brain damage manifesting as autism consequent to the development of an "enterocolitis" in the immediate post-vaccination period.

Aim: To assess if MMR vaccination is associated with subclinical intestinal inflammation, which is central to the autistic "enterocolitis" theory.

Methods: We studied 109/58 infants, before and two and four weeks after immunisation with Pentavac and MMR vaccines, for the presence of intestinal inflammation (faecal calprotectin).

Results: Neither vaccination was associated with any significant increase in faecal calprotectin concentrations.

Conclusions: The failure of the MMR vaccination to cause an intestinal inflammatory response provides evidence against the proposed gut-brain interaction that is central to the autistic "enterocolitis" hypothesis.

The presence of lymphoid nodular hyperplasia and colitis in autistic children, termed autistic “enterocolitis”, with various gastrointestinal symptoms investigated a number of years after immunisation is not in doubt. However, the aetiology and pathogenesis of the intestinal inflammation is controversial as is the possible role of the intestine in the development of the central nervous system dysfunction that may manifest in mental health disorders.

One hypothesis of the pathophysiology of autistic “enterocolitis” postulates that the measles vaccination virus of the measles, mumps, and rubella (MMR) vaccine escapes initial detection by the immune system and disseminates to the intestinal lymphoid tissue. Here, it is suggested, it leads to an “enterocolitis” with increased permeation of neurotoxic luminal substances during a vulnerable part of brain development, leading to regressive autism. Central to this hypothesis is the development of intestinal inflammation in the immediate period following vaccination.

We tested this hypothesis by assessing intestinal inflammation (faecal calprotectin) before and after Pentavac and MMR vaccination in a group of infants.

SUBJECTS AND METHODS

Iceland has a developed health service with a centralised vaccination programme that results in infant vaccination rates approaching 100%. Pentavac (Pasteur Mérieux, France) vaccination (against diphtheria, tetanus, pertussis, polio, Haemophilus influenza type b) is performed at three, five, and 12 months of age and MMR (Priorix; SmithKline Beecham) vaccination at 18 months. One hundred and nine infants attending two of the vaccination centres of Southwest Iceland participated. These were consecutive infants where the parents had been sent a pre-attendance information leaflet explaining the nature and aims of the research. All of those approached participated. No infant met the predetermined specific exclusion criteria to this study which included those specified by the makers of the vaccines, the presence of intestinal diseases, or ingestion of medications that are associated with intestinal permeability-inflammation.

The infants were studied by measuring faecal calprotectin (Calprest, Calprotech Ltd, London, UK) one week before Pentavac (at 12 months of age) and MMR (at 18 months) vaccination, and two and four weeks later, respectively. Pentavac does not contain mercury, which has been proposed to predispose to the toxicity of MMR.

<table>
<thead>
<tr>
<th>Table 1 Faecal calprotectin concentrations (mg/l) before and after Pentavac and measles-mumps-rubella (MMR) vaccination</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pentavac</strong></td>
</tr>
<tr>
<td>Pre</td>
</tr>
<tr>
<td>0 week</td>
</tr>
<tr>
<td>n</td>
</tr>
<tr>
<td>Median</td>
</tr>
</tbody>
</table>

There were no significant differences between calprotectin levels at the different time points and sequential studies showed no significant changes following vaccination.

Abbreviations: MMR, measles-mumps-rubella.
intestinal pathology of the measles vaccination virus in the development of this parable with published data in normal infants of the same data) before vaccinations at 12 and 18 months of age are compared in infants undergoing immunisation. The upper limit of faecal MMR vaccination leads to subclinical intestinal inflammation. gastrointestinal symptoms.

Sensitivity perhaps immune compromised or with an immunological might have an adverse effect on susceptible infants that are does not however rule out the possibility that vaccination inflammatory response suggests that the measles vaccine has caused equal inter-

studies were approved by the National University Hospital Ethics Committee.

ACKNOWLEDGEMENT

The study was supported by the Science Fund of the University Hospital Hringbraut Reykjavik and by Wyeth Lederle

DISCUSSION

Naturally occurring measles viral infection has a predilection for the intestinal lymphoid tissue and may cause intestinal inflammation, which on occasions may resemble Crohn’s disease. The measles virus has controversially been implicated in the pathogenesis of Crohn’s disease and other diseases, including multiple sclerosis. The suggestion that the live attenuated measles vaccine might lead to ileocolonic inflammation with autonomic features has caused equal interest. This hypothesis was formulated in an attempt to explain the high prevalence of “enterocolitis” in autistic children with gastrointestinal symptoms. Consequent to the measles vaccine virus induced ileocolonic inflammation, it is suggested, there is increased intestinal permeation of a variety of intestinally derived neuroactive peptides that interfere with brain development. In support of this hypothesis are reports of intestinal pathology and abnormal intestinal function in children with autism when examined a number of years after the vaccination. These data are not particularly controversial but rather highlight the possible role and effect of the measles vaccination virus in the development of this inflammation in the immediate post-vaccination period and the postulated consequent effect on brain function. In this study we specifically assessed the possibility that MMR vaccination leads to subclinical intestinal inflammation in infants undergoing immunisation. The upper limit of faecal concentrations of calprotectin (110 mg/l; 95% confidence limits (2 SD) calculated from logarithmically transformed mean data) before vaccinations at 12 and 18 months of age are comparable with published data in normal infants of the same age and are twice as high as those reported in healthy adults. Pathological intestinal inflammation is easily differentiated from normal as faecal calprotectin values are usually well in excess of 1000 mg/l under these circumstances.

There was no evidence that either Pentavac or MMR vaccination provoked subclinical intestinal inflammation in any of our apparently healthy children during the four week post-vaccination period. This lack of a detectable intestinal inflammatory response suggests that the measles vaccine virus itself is not enterotoxic in healthy infants which argues against the MMR induced autistic “enterocolitis” theory. This does not however rule out the possibility that vaccination might have an adverse effect on susceptible infants that are perhaps immune compromised or with an immunological makeup that predisposes them to autoimmune disease.

ACKNOWLEDGEMENT

The study was supported by the Science Fund of the University Hospital Hringbraut Reykjavík and by Wyeth Lederle

REFERENCES

Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine

B Thjodleifsson, K Davídsdóttir, U Agnarsson, G Sigthórsson, M Kjeld and I Bjarnason

Gut 2002 51: 816-817
doi: 10.1136/gut.51.6.816

Updated information and services can be found at:
http://gut.bmj.com/content/51/6/816

These include:

References
This article cites 28 articles, 4 of which you can access for free at:
http://gut.bmj.com/content/51/6/816#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/